Key facts
- This page summarizes Camille Sebaaly's Form 4 filing for Sunshine Biopharma, Inc (SBFM).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Dec 2022, 05:01.
Camille Sebaaly - 30 Nov 2022 Form 4 Insider Report for Sunshine Biopharma, Inc (SBFM)
- Reporting relationship
- CFO/Secretary
- Issuer ticker
- SBFM
- Reported as of
- 30 Nov 2022
- Net transaction value
- +$22,905
- SEC form
- 4
- Accepted by SEC
- 02 Dec 2022, 05:01:11 UTC
- Prior SEC filing
- 06 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Camille Sebaaly
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Camille Sebaaly filed Form 4 for Sunshine Biopharma, Inc (SBFM) on 02 Dec 2022.
Change
- Previous filing in this sequence was filed on 06 Jun 2022.
- Current net transaction value: +$22,905.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SBFM
transaction
Common Stock
Purchase
- Transaction value
- $22,905
- Shares
- +30,000
- Change %
- +21%
- Price
- $0.7635
- Shares after
- 174,465
- Date
- 30 Nov 2022
- Ownership
- Direct
* marks a reported price that did not pass the local price check.